Selection of a human anti-RhD monoclonal antibody for therapeutic use : impact of IgG glycosylation on activating and inhibitory Fc gamma R functions

The substitution of plasmatic anti-RhD polyclonal antibodies by a monoclonal antibody (mAb) for preventing the hemolytic disease of the newborn (HDN) is an important issue due to supply and safety concerns. Since it has been suggested that FcgammaR are involved in the prevention of HDN, the in vitro...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 118(2006), 2-3 vom: 13. Feb., Seite 170-9
1. Verfasser: Sibéril, Sophie (VerfasserIn)
Weitere Verfasser: de Romeuf, Christophe, Bihoreau, Nicolas, Fernandez, Nadine, Meterreau, Jean-Luc, Regenman, Annie, Nony, Emmanuel, Gaucher, Christine, Glacet, Arnaud, Jorieux, Sylvie, Klein, Philippe, Hogarth, Mark P, Fridman, Wolf-Herman, Bourel, Dominique, Béliard, Roland, Teillaud, Jean-Luc
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Comparative Study Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal FCGR2B protein, human FCGR3A protein, human Fcgr3 protein, mouse Immunoglobulin G Receptors, IgG Rh-Hr Blood-Group System Rho(D) antigen